Sutro Biopharma, Inc. - Common Stock, $0.001 par value (STRO) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2018 to Q4 2025

Type / Class
Equity / Common Stock, $0.001 par value
Symbol
STRO on Nasdaq
Shares outstanding
84,733,230
Price per share
$11.57
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
290,035
Total reported value
$3,355,706
% of total 13F portfolios
0%
Share change
-53,068,984
Value change
-$74,010,433
Number of holders
6
Price from insider filings
$11.57
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Sutro Biopharma, Inc. - Common Stock, $0.001 par value (STRO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Affinity Asset Advisors, LLC 7.8% $5,717,348 6,583,772 Affinity Healthcare Fund, LP 16 Oct 2025
MILLENNIUM MANAGEMENT LLC 5.6% $4,434,182 4,717,215 Millennium Management LLC 27 Jun 2025
VANGUARD GROUP INC 4.9% $2,937,877 4,115,250 The Vanguard Group 30 Jun 2025
BlackRock, Inc. 2.5% -69% $1,493,679 -$2,892,242 2,092,281 -66% BlackRock, Inc. 30 Jun 2025

As of 31 Dec 2025, 6 institutional investors reported holding 290,035 shares of Sutro Biopharma, Inc. - Common Stock, $0.001 par value (STRO). This represents 0.34% of the company’s total 84,733,230 outstanding shares.

Institutional Holders of Sutro Biopharma, Inc. - Common Stock, $0.001 par value (STRO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 290,035 $3,355,706 -$74,010,433 $11.57 6
2025 Q3 53,391,796 $46,361,876 -$1,653,951 $0.87 85
2025 Q2 55,585,121 $39,680,994 -$3,651,726 $0.71 100
2025 Q1 61,457,334 $39,985,859 -$10,841,219 $0.65 113
2024 Q4 63,895,959 $117,565,386 -$7,306,459 $1.84 122
2024 Q3 62,516,525 $216,373,636 -$1,660,759 $3.46 130
2024 Q2 63,167,394 $185,075,042 +$25,139,079 $2.93 119
2024 Q1 53,412,221 $301,719,025 +$2,094,339 $5.65 116
2023 Q4 55,648,249 $238,729,642 -$219,480 $4.29 113
2023 Q3 55,996,442 $194,308,615 +$5,622,550 $3.47 108
2023 Q2 54,105,078 $251,585,717 +$2,181,872 $4.65 119
2023 Q1 53,720,779 $247,499,715 +$10,470,599 $4.62 114
2022 Q4 49,984,035 $403,859,817 +$6,296,600 $8.08 116
2022 Q3 50,396,383 $279,697,401 +$23,514,794 $5.55 111
2022 Q2 46,245,672 $240,931,373 +$15,713,924 $5.21 111
2022 Q1 41,606,389 $341,990,813 -$38,514,469 $8.22 111
2021 Q4 39,677,298 $590,411,817 -$4,363,219 $14.88 114
2021 Q3 39,817,120 $752,214,523 -$26,368,206 $18.89 119
2021 Q2 41,241,047 $766,657,023 -$71,886,996 $18.59 121
2021 Q1 44,209,991 $1,005,487,689 +$114,863,310 $22.76 136
2020 Q4 39,392,744 $855,224,796 +$184,675,658 $21.71 132
2020 Q3 31,151,440 $313,088,624 +$67,545,691 $10.05 87
2020 Q2 23,997,579 $186,238,799 +$97,614,730 $7.76 76
2020 Q1 11,868,607 $116,270,683 +$7,872,102 $10.20 60
2019 Q4 11,616,437 $127,772,633 +$7,088,075 $11.00 64
2019 Q3 11,074,608 $91,621,057 -$8,301,817 $9.09 59
2019 Q2 11,817,484 $122,739,770 +$6,666,665 $11.38 58
2019 Q1 11,231,778 $116,185,606 +$4,727,906 $11.39 49
2018 Q4 9,707,399 $87,234,000 -$10,616,486 $9.02 41
2018 Q3 9,086,875 $135,767,000 +$129,306,000 $15.00 32